Kihealth Inc.
June 23, 2026
Theater 1
Type: Company Presentation
Focus Area:
Diagnostics and Personalized Medicine
Kihealth is building a next-generation diagnostics platform that detects disease at the cellular level, years before symptoms or standard biomarkers emerge. The company’s proprietary liquid biopsy technology measures organ-specific cell death using epigenetic signatures in circulating DNA, creating a new category of early-disease detection. Its initial focus is diabetes, where its beta cell assay provides a real-time view of pancreatic health, unlocking earlier intervention and improved therapeutic decision-making. This innovation was recognized with the 2025 American Diabetes Association Innovation of the Year award, highlighting its potential to transform early diabetes detection and care. With applications across metabolic, autoimmune, and neurodegenerative diseases, Kihealth is positioned to become a foundational layer in preventive healthcare and precision medicine.
Company HQ City:
Saint Augustine
Company HQ State:
FL
Company HQ Country:
United States
Year Founded:
2023
Lead Product in Development:
Kihealth’s lead product is a novel liquid biopsy designed to measure pancreatic beta cell death through detection of organ-specific cell-free DNA. By identifying early cellular injury before changes in glucose or HbA1c, the test provides a real-time view of disease progression, enabling earlier intervention, improved risk stratification, and more precise therapeutic decision-making in both Type 1 and Type 2 diabetes.
CEO
Jennifer Anderson, CEO
Development Phase of Lead Product
NDA Preparation/In Review
Number of Unlicensed Products Looking for Licensing
2
When you expect your next catalyst update?
November, 2026
What is your next catalyst (value inflection) update?
Kihealth’s next major value inflection will be achieving FDA clearance for its lead beta cell assay, alongside initial clinical readouts for its second indication in pancreatic cancer. Together, these milestones validate both the regulatory pathway and the broader platform’s ability to detect organ-specific disease earlier across multiple indications.
Primary Speaker
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}